Evolus, Inc.

EOLS

US30052C1071

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
12.77 ^USD	+1.27%		-4.84%	+21.27%

May. 11	Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	CI
May. 11	Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	CI

Evolus, Inc. Announces Retirement of Lauren Silvernail as Executive Vice President of Corporate Development, Effective May 31, 2022

March 03, 2022 at 04:05 pm EST

Evolus, Inc. announced that Lauren Silvernail will retire from her position as Executive Vice President of Corporate Development effective May 31, 2022.

Latest news about Evolus, Inc.

Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	May. 10	CI
Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	May. 10	CI
Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	May. 10	CI
Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Transcript : Evolus, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (EOLS) EVOLUS Reports Q1 Revenue $59.3M, vs. Street Est of $57.3M	May. 07	MT
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024	May. 07	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26	RE
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	Apr. 17	CI
Evolus, Inc. Announces Board Changes	Apr. 03	CI
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing	Mar. 22	MT
Transcript : Evolus, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM	Mar. 13
Evolus Prices $50 Million Share Offering	Mar. 11	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 08	MT
Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating	Mar. 08	MT
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours	Mar. 07	MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Transcript : Evolus, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M	Mar. 07	MT
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024	Mar. 07	CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 29	MT
Evolus Shares Rise After Upgrade From Barclays	Jan. 29	MT

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Sector

Pharmaceuticals

Calendar

2024-06-06 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Evolus, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.77 USD

Average target price

22.29 USD

Spread / Average Target

+74.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOLUS, INC.	+21.27%	800M
NOVO NORDISK A/S	+31.80%	588B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	326B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.21%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-7.20%	200B
AMGEN INC.	+8.12%	167B
PFIZER, INC.	-1.42%	161B

Other Pharmaceuticals

Evolus, Inc.

Equities

EOLS

US30052C1071

Pharmaceuticals

Evolus, Inc. Announces Retirement of Lauren Silvernail as Executive Vice President of Corporate Development, Effective May 31, 2022

Latest news about Evolus, Inc.

Chart Evolus, Inc.

Company Profile

Income Statement Evolution

Ratings for Evolus, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals